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Purpose
Ipilimumab improves survival in advanced melanoma patients. However, the efficacy and
safety of ipilimumab has not been evaluated in Asian melanoma patients with a high fre-
quency of mucosal and acral melanoma subtypes.
Materials and Methods
Advanced melanoma patients treated with 3 mg/kg ipilimumab in a Korean multicenter
named-patient program (NPP) were evaluated between September 2014 and July 2015.
Baseline characteristics and blood parameters including neutrophil to lymphocyte ratio
(NLR) were assessed, and outcome and adverse events were evaluated according to sub-
types. 
Results
A total of 104 advanced melanoma patients were treated. The primary sites were acral
(31.7%), mucosal (26%), cutaneous (26%), uveal (9.6%), and unknown (6.7%). Sixty-eight
patients (65.4%) experienced adverse events, and the most common toxicity was skin rash
(22.1%), 10 patients (9.6%) experienced adverse events of grade 3 or higher. The median
progression-free survival (PFS) was 2.73 months (95% confidence interval, 2.67 to 2.85),
and there was no difference in PFS according to subtypes. Poor performance status, liver
metastasis, and NLR ( 5) were independent poor prognostic factors by multivariate analy-
sis.  
Conclusion
In the Korean NPP cohort, ipilimumab showed similar efficacy and tolerability compared to
Western patients, regardless of subtypes. All subtypes should benefit from ipilimumab with
consideration of performance status, liver metastasis, and NLR. 
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Introduction
Malignant melanoma is one of the most aggressive cancers
and its incidence has shown a rapid increase [1-3]. Many
treatments for melanoma, including chemotherapies, immu-
notherapies, and combined biochemotherapy regimens have
been utilized but have failed to significantly improve out-
come and the median overall survival (OS) of metastatic
melanoma is approximately 8 months [4]. However, studies
reported in recent years have resulted in many break-
throughs in the melanoma field. Two extraordinary advances
were recently achieved with positive results from two sepa-
rate studies of new therapies, ipilimumab [5] in immunother-
apy and vemurafenib [6] in molecular targeted therapy.
Ipilimumab (Yervoy, Bristol-Myers Squibb) is a fully
human monoclonal antibody against the cytotoxic T-lym-
phocyte–associated antigen 4 receptor. In phase III clinical
trials, treatment with ipilimumab resulted in a statistically
significant improvement in OS of patients with metastatic
melanoma [5]. A pooled analysis of 1,861 patients treated
with ipilimumab showed long-term survival with a 3-year
survival rate of 22% [7]. In addition, many expanded access
programs (EAP) in various countries reported on the benefit
of ipilimumab in a real world setting [8]. Compared to West-
ern countries, the incidence of melanoma in Eastern counties
is very low but has also increased [9]. The most common sub-
type in Western countries is cutaneous melanoma, while
acral and mucosal melanoma are the most common subtypes
in Eastern countries [9-12]. Ipilimumab has been approved
in Asian countries including Korea; however, data on the 
efficacy and safety of ipilimumab in Asian patients with
melanoma were limited. 
Therefore, we reported the outcomes of ipilimumab in 
Korean patients enrolled in the named-patient program
(NPP) cohort. In addition, we examined the association 
between response to ipilimumab and melanoma subtype,
BRAF mutation, and blood parameters.
Materials and Methods
1. Patients’ inclusion and treatment plan 
Patients who met the following eligibility criteria were 
enrolled in the ipilimumab NPP; a histologically confirmed
stage IV malignant melanoma according to the American
Joint Committee on Cancer (AJCC), and Eastern Cooperative
Oncology Group (ECOG) performance status (PS) 0, 1, or 2.
All patients received four cycles of 3 mg/kg ipilimumab
every 3 weeks, unless severe adverse events (AEs) or rapid
progression of disease occurred. M-stage was defined 
according to site metastasis in combination with elevated lac-
tate dehydrogenase (LDH) levels, as described previously
[13]. Records of all patients who received at least one dose of
ipilimumab were reviewed retrospectively. The study pro-
tocol was approved by the ethics committee from all six hos-
pitals and this study was conducted according to the
Declaration of Helsinki.  
2. Data collection 
The medical records of eligible patients were retrieved and
included age, sex, ECOG PS, previous therapies, melanoma
subtype and disease stage, metastatic site, LDH, and BRAF
and c-KIT mutational status if available. Treatment-related
AEs using the Common Terminology Criteria for Adverse
Events ver. 4.0; hematological and serum parameters includ-
ing absolute neutrophil count (ANC), and lymphocyte count;
date of progression; and reason for cessation of ipilimumab
(progressive disease, AE, and death) were also collected. 
Patients were reviewed routinely every 3 weeks during treat-
ment and every 8 weeks during follow-up. Radiological 
imaging was generally performed 6-9 weeks after ipili-
mumab induction and every 8 weeks thereafter. Responses
were scored according to Response Evaluation Criteria in
Solid Tumor (RECIST) ver. 1.1 criteria.
3. Statistical analysis 
Baseline, pre-treatment white blood cell count, ANC, 
absolute lymphocyte count (ALC), neutrophil to lymphocyte
ratio (NLR), and serum LDH were analyzed. Progression-
free survival (PFS) was defined as the time from the start of
ipilimumab to the onset of progression or death. Patients
without progression and still alive at the time of analysis
were censored. OS was defined as the time from the start of
ipilimumab to death from any cause. Univariate analysis for
clinical and laboratory parameters was performed with 
respect to OS and PFS. Survival curves of categorical vari-
ables were calculated using the Kaplan-Meier method and
compared using the log-rank test. Continuous variables in
association with survival outcomes were examined by means
of martingale residuals. Multivariate models of patient and
tumor characteristics in association with PFS and OS were
based on Cox proportional hazards regression analyses.
Two-tailed p < 0.05 was considered statistically significant
for all analyses. SPSS ver. 15.0 (SPSS Inc., Chicago, IL) was
used for data analysis.
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Results
1. Patient characteristics
Between September 2014 and July 2015, 104 patients were
treated with ipilimumab at six Korean hospitals. Patients’
characteristics are summarized in Table 1. The median age
of patients was 58 years (interquartile range, 50 to 66) and 51 
patients (49%) were male. The most common subtype was
acral melanoma (33 patients, 31.7%), 27 patients (26%) had
mucosal melanoma, and 27 patients (26%) had skin
melanoma. All 104 patients had AJCC stage IV melanoma,
and the majority of patients were stage M1c (76%). Sixty-two
patients (65.3%) had elevated baseline LDH and 20 patients
(19.2%) had NLR  5. BRAF and c-KIT mutations were eval-
uated in 87 and 54 patients, respectively, and the incidence
of BRAF and c-KIT mutations was 18.4% and 13.0%, respec-
tively. Approximately 40% of patients received ipilimumab
as first line treatment, and 28% patients had received at least
three prior systemic therapies, median number of prior sys-
temic treatments was two (range, 1 to 5). Sixty-nine patients
(66.3%) received all four doses of ipilimumab, and nine 
patients received three doses, 11 patients received two doses,
and 15 patients received one dose. The most common reason
for drug discontinuation was rapid disease progression.  
2. Safety
Of all patients, 68 patients (65.4%) experienced treatment
related AEs of any grade (Table 2), and the most common
toxicities were pruritus (31.7%) and skin rash (22.1%). The
majority of treatment related AEs were grade 1 or 2, and
were generally manageable and reversible without sequelae.
Ten patients (9.6%) experienced grade 3 toxicities, and seven
patients experienced treatment related AEs, and three cases
were considered to be disease related events. One patient
suffered from grade 3 fatigue and grade 2 nausea after two
cycles of ipilimumab and brain metastasis was detected on
brain magnetic resonance imaging. One patient developed
grade 3 elevation of aspartate aminotransferase (AST)/ala-
nine aminotransferase (ALT) after three cycles of ipilimumab
and showed progression of liver metastasis according to 
RECIST ver. 1.1 criteria. One patient complained of grade 3
generalized pain, which improved to grade 1 after morphine
treatment. No patient experienced grade 4 or 5 AEs, and
there were no immune response related serious AEs.
Table 1 . Baseline characteristics
Variable No. (%)
Age, median (IQR, yr) 58 (50-66)
Sex
Male 51 (49)
Female 53 (51)
ECOG PS
0 28 (26.9)
1 64 (61.5)
2 12 (11.5)
Primary site
Acral 33 (31.7)
Mucosal 27 (26)
Cutaneous 27 (26)
Uveal 10 (9.6)
Primary origin unknown 7 (6.7)
M stage (LDH included)
M1a 17 (16.3)
M1b 8 (7.7)
M1c 79 (76)
Patients with liver metastasis
Yes 35 (33.7)
No 69 (66.3)
Patients with brain metastasis
Yes 13 (12.5)
No 91 (87.5)
Elevated LDH (n=95)
Yes 62 (65.3)
No 33 (32.7)
Neutrophil to lymphocyte ratio
< 5 84 (80.8)
 5 20 (19.2)
BRAF mutation (n=87)
Mutant 16 (18.4)
Wild type 71 (71.6)
c-KIT mutation (n=54)
Mutant 7 (13)
Wild type 47 (87)
No. of previous therapies
1 41 (39.4)
2 34 (32.7)
 3 29 (27.9)
IQR, interquartile range; ECOG PS, Eastern Cooperative Oncol-
ogy Group performance status; LDH, lactate dehydrogenase.
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3. Efficacy
Tumor response was evaluated in 101 of 104 patients. Four
patients (3.8%) showed complete response (CR) and five 
patients (4.8%) showed a partial response (PR) by RECIST.
The overall response rate (ORR=CR+PR) and disease control
rate (DCR=CR+PR+stable disease) was 8.6% and 29.8%, 
respectively (Table 3). The median follow-up duration was
7.1 months (95% confidential interval [CI], 5.96 to 8.30), and
85 patients (81.7%) had progression of disease and 30 
patients (28.8%) had died by the time of this analysis. The
median PFS was 2.73 months (95% CI, 2.67 to 2.85) in all 
patients (Fig. 1A), and significantly longer survival was 
observed for patients with disease control (CR+PR+stable
disease) compared to those with progressed disease (PD)
(median PFS, 5.4 months vs. 2.2 months; p < 0.001) (Fig. 1B
and C).
4. Association between baseline characteristics and efficacy
There was no difference in ORR, DCR, PFS, or OS accord-
ing to melanoma subtypes (Fig. 1D and E). Pretreatment 
median ANC was significantly higher in patients with PD
compared to those who achieved disease control (4,017
cells/µL vs. 3,183 cells/µL, p=0.016), while pretreatment 
median ALC was significantly lower in patients with PD
compared to those who achieved disease control (1,530
cells/µL vs. 1,833 cells/µL, p=0.049). When ANC and ALC
were incorporated in the NLR, significantly higher NLR was
observed in patients who experienced PD than in those with
disease control (2.63 vs. 1.90, p=0.003) (Table 4). In addition,
we found that PFS and OS were significantly longer in 
patients with low NLR compared to those with high NLR
(median PFS, 2.8 vs. 1.3 months; p < 0.001 and median OS,
not reached vs. 2.6 months; p < 0.001) (Fig. 1F and G). In uni-
variate analysis between baseline characteristics and sur-
vival, ECOG PS, AJCC M stage, liver metastasis, and NLR
showed significant association with PFS, and ECOG PS and
NLR showed significant association with OS. There was no
difference in PFS and OS according to the presence of brain
metastasis, BRAF mutation, c-KIT mutation, and LDH eleva-
tion before treatment, or the number of previous therapies.
In multivariate analysis, ECOG PS, liver metastasis, and NLR
were independent prognostic factors for PFS, and ECOG PS
and liver metastasis were independent prognostic factors for
OS (Table 5). For selection of patients likely to benefit from
ipilimumab, the patients were divided into three groups
based on independent prognostic factors for PFS and OS, 
Adverse event  
No. (%) (n=104)
Grade 1 Grade 2 Grade 3 Grade 4
Immune related
Diarrhea 6 (5.8) 1 (1.0) 0 (0.0) 0 
Rash 17 (16.3) 5 (4.8) 1 (1.0) 0
Pruritus 14 (13.5) 18 (17.3) 1 (1.0) 0
Thyroiditis 1 (1.0) 1 (1.0) 0 (0.0) 0
Non-immune related
Nausea 7 (6.7) 4 (3.8) 1 (1.0) 0
Vomiting 3 (2.9) 2 (1.9) 0 (0.0) 0
Fatigue 13 (12.5) 6 (5.8) 3 (2.9) 0
Pain 8 (7.7) 7 (6.7) 1 (1.0) 0
Dyspnea 2 (1.9) 4 (3.8) 0 (0.0) 0
Edema 2 (1.9) 0 (0.0) 1 (1.0) 0
Elevated AST/ALT 0 (0.0) 0 (0.0) 1 (1.0) 0
Anemia 0 (0.0) 1 (1.0) 1 (1.0) 0
AST, aspartate aminotransferase; ALT, alanine aminotransferase.
Table 2. Treatment-related adverse events
Table 3. Tumor response by RECIST ver. 1.1 
Best overall response No. (%)
Complete response 4 (3.8)
Partial response 5 (4.8)
Stable disease 22 (21.2)
Progressive disease 70 (67.3)
Not assessed 3 (2.9)
RECIST, Response Evaluation Criteria in Solid Tumor. 
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Fig. 1. Kaplan-Meier curves. (A) Progression-free survival (PFS) and overall survival (OS) in all patients. (B) PFS according
to response. (C) OS according to response. (D) PFS according to primary site. (E) OS according to primary site. (F) PFS 
according to according to neutrophil to lymphocyte ratio (NLR). (G) OS according to according to NLR. (H) PFS according
to risk factors (Eastern Cooperative Oncology Group performance status [ECOG PS] [0-1 vs. 2], liver metastasis [no vs. yes],
and NLR [< 5 or  5]). (I) OS according to risk factors (ECOG PS [0-1 vs. 2] and liver metastasis [no vs. yes]). DC, disease con-
trol (complete response+partial response+stable disease); PD, progression of disease. (Continued to the next page)
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Table 4. Blood parameters at baseline according to on-treatment response to ipilimumab
Response WBC count p-value ANC p-value ALC count p-value NLR p-value(cells/µL) (cells/µL) (cells/µL)
CR+PR+SD 5,320 (4,950-6,670) 0.076 3,183 (2,480-3,742) 0.016 1,833 (1,368-2,468) 0.049 1.90 (1.24-2.45) 0.003
PD 6,140 (5,230-8,750) 4,017 (2,863-5,784) 1,530 (1,110-1,955) 2.63 (1.76-5.14)
Values are presented as median (interquartile range). WBC, white blood cell; ANC, absolute neutrophil count; ALC, absolute
lymphocyte count; NLR, neutrophil to lymphocyte ratio; CR, complete response; PR, partial response; SD, stable disease;
PD, progressed disease.
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Fig. 1. (Continued from the previous page)
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respectively. Patients without adverse factors had longer PFS
and OS than patients with adverse factors (Fig. 1H and I).
Discussion
Ipilimumab improved survival in several clinical trials and
many EAPs in pretreated and treatment-naïve patients with
advanced melanoma [3,7,8]. However, due to low disease 
incidence, clinical trials and EAPs with ipilimumab have 
excluded Asian patients with advanced melanoma, therefore
efficacy and safety data on ipilimumab in the Asian patient
population has been limited. We report outcomes with ipili-
mumab in a real-world routine clinical setting in Asian 
patients with different melanoma subtypes compared to
Western patients. Although the median duration of follow-
up was 7 months, ipilimumab showed consistent efficacy
compared to Western patients with advanced melanoma
[3,7,8,14,15].
Malignant melanoma has demographic and ethnic differ-
ences. It is the fifth most common cancer in the United States;
however, its incidence is relatively rare among Africans, His-
panics, and Asians [1,16]. The histologic subtype also differs,
with the most common histology being superficial spreading
melanoma in whites and acral lentiginous melanoma among
blacks [17]. According to recent data, the most common pri-
mary site in Asians [9-12] was acral lentiginous melanoma.
Mucosal melanoma is the second most common primary site
in patients in China and Korea [10,11], although it is 
extremely rare in Caucasians [18]. In patients from Western
countries, there were no reported differences in efficacy of
ipilimumab in patients with primary acral and mucosal
melanoma compared with cutaneous melanoma [8,19]. In the
current study, the most common subtype was acral and 
mucosal melanoma (57.7%) with no survival differences 
according to subtypes.  
Although the follow up duration was not long, the median
OS was not yet reached and the median PFS was 2.73 months
(95% CI, 2.67 to 2.85). These results are comparable to those
of Western patients treated with ipilimumab [3,7,8,14,15],
and the ORR of 8.6% and DCR of 29.8% were similar to EAP
data in Western countries [3,7,8,14,15]. 
Only two small studies of ipilimumab in Asians have been
reported. In a prospective phase II trial in 20 previously 
untreated Japanese patients, the median PFS was 2.74
months [20]. The second study was an EAP study in 31 pre-
viously treated Taiwanese patients, which reported a PFS of
4.1 months [21]. Therefore, ipilimumab is a feasible treatment
option for Asian patients with metastatic melanoma.
For identification of predictive markers of efficacy for ipil-
imumab, we analyzed the association between the survival
and baseline characteristics including blood parameters. Sev-
eral blood parameters, including LDH, ANC, ALC, NLR, and
C-reactive protein, have been suggested as associated mark-
ers with efficacy of ipilimumab [8,15,19,22-24]. In univariate
analysis, ECOG PS, AJCC M stage, liver metastasis, and NLR
showed significant association with PFS, and ECOG PS and
NLR showed significant association with OS. There was no
difference in PFS and OS according to brain metastasis or the
number of previous therapies. In multivariate analysis,
ECOG PS, liver metastasis, and NLR were independent prog-
nostic factors for PFS and ECOG PS and liver metastasis were
independent prognostic factors for OS. In addition, patients
without adverse factors had longer survival than those with
adverse factors. Therefore, ipilimumab could be adminis-
tered in patients with good PS, lower NLR, and no liver
metastasis.  
The safety of ipilimumab in the current study was similar
to that reported in patients with cutaneous melanoma [25].
There were no treatment-related deaths or withdrawal from
the study due to drug-related AEs. The most frequent toxic-
ities were immune-related skin toxicities. Despite develop-
ment of colitis in seven patients (6.7%), there were no grade
3 or higher severe cases, and there was no immune related
hepatitis. One patient with multiple liver metastases had 
elevated AST/ALT of grade 3 after two cycles of ipilimumab,
and computed tomography scan showed a further increase
in size and numerous liver metastatic nodules and masses,
replacing almost the entire liver. Therefore, we considered
that the hepatitis was related to disease progression, not 
ipilimumab. Twenty-two patients (20.3%) suffered from 
fatigue; however, these patients had poor PS (ECOG PS 1 or
2) or heavy tumor burden at the baseline, thus this symptom
could be disease-related.
There are several limitations in this study, which are com-
mon in retrospective cohort studies, including potential 
patient selection bias, lack of strict methods of timing of 
assessments, and some missing data of toxicity profiles.
Among 104 patients, 69 patients (66.4%) received all four
doses of ipilimumab, and 15 patients completed only one
treatment cycle. The most common reason for discontinua-
tion of ipilimumab was rapid disease progression, because
some patients with severe tumor burden who did not have
other treatment options had to wait for approval of the NPP
before receiving treatment with ipilimumab. Despite these
limitations, because the NPP population included patients
who would have been excluded from a clinical trial due to
their poor medical condition, our result may be more repre-
sentative of advanced melanoma patients in the clinical set-
ting. In the Korean melanoma patients, ipilimumab showed
a similar efficacy and tolerability compared with Western 
patients, regardless of subtypes. All subtypes should benefit
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from ipilimumab with consideration of PS, liver metastasis,
and NLR.
Conclusion
The current NPP cohort in Korean patients with advanced
melanoma showed that ipilimumab monotherapy had a
manageable safety profile and antitumor activity. These find-
ings are consistent with the safety and activity profile of 
ipilimumab in Asian patients who had mainly acral and 
mucosal melanoma compared to patients with cutaneous
melanoma from Western studies.
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